Patheon Pharmaceuticals Inc.

Form 483 issued March 11, 2016 · Cincinnati, Ohio

Inspection
Mar 1 – Mar 11, 2016
Observations
2
Pages
4
FEI number
1510437

In short: On March 11, 2016, FDA issued a Form 483 with 2 observations to Patheon Pharmaceuticals Inc. in Cincinnati, Ohio (FEI 1510437) after an inspection that ran Mar 1 – Mar 11, 2016. The investigators were Christopher T. Middendorf and Lauren N. Smith. Most observations concern quality system; the most-cited regulation is 21 CFR 211.192 (production record review).

At a glance

2 of 2 observations on this 483 concern quality system.

Quality system2

Most cited: 21 CFR 211.192 (1×) · 211.22 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch…

  2. 02

    The responsibilities and procedures applicable to the quality control unit…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Patheon Pharmaceuticals Inc.?

FDA listed 2 observations on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.192 (production record review). The opening words of each observation are shown on this page.

Who inspected Patheon Pharmaceuticals Inc.?

Christopher T. Middendorf and Lauren N. Smith are named on this Form 483, for the inspection of Mar 1 – Mar 11, 2016. Each investigator has a profile showing what they cite most.

When was Patheon Pharmaceuticals Inc. inspected by FDA?

The inspection ran Mar 1 – Mar 11, 2016, and the Form 483 is dated March 11, 2016.

How do I get the full Form 483 for Patheon Pharmaceuticals Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free